Tables

Page last updated: September 2016

• Table 1.1.1 Key components of the clinical issue addressed by the submission
• Table 1.1.2 PBAC submission history
• Table 1.3.1 Progress of TGA application for registration of proposed medicine
• Table 1.4.1 Essential elements of the requested listing
• Table 1.4.2 Essential elements of the requested listing for chemotherapy medicines
• Table 2.3.1 Information required to assess the risk of bias in randomised trials
• Table 2.3.2 Flow of participants through the trials
• Table 2.4.1 Example presentation of differences in trial outcomes or analyses
• Table 2.4.2 Details of proposed minimal clinically important differences (MCIDs) for outcomes in the included trials
• Table 2.5.1 Results of [outcome] across the studies: dichotomous data
• Table 2.5.2 Results of [outcome] across the studies: continuous data (with outcome presented as change from baseline)
• Table 2.5.3 Results of [outcome] across the studies: time-to-event data
• Table 2.6.1 Results of [outcome] within the studies: dichotomous data
• Table 2.6.2 Example of adapted results tables to include relevant information on pooled results
• Table 2.6.3 Steps to assess the transitivity assumption
• Table 2.6.4 Summary of results of the indirect comparison (for a dichotomous outcome)
• Table 2.6.5 Extent of treatment switching in the randomised trials (cumulative across follow-up periods)
• Table 2.7.1 Example differences between the trial setting and the Australian setting in terms of population, disease or condition, circumstances or treatments
• Table 3A.1.1 Key components of the economic evaluation
• Table 3A.5.1 Identification of health outcomes used in the model
• Table 3A.6.1 Indicative list of health care resource items, unit costs and usage included in the economic evaluation
• Table 3A.8.1 Presentation of the stepped derivation of the base-case economic evaluation from the clinical study data
• Table 3A.8.2 Health care resource items: disaggregated summary of cost impacts in the economic evaluation
• Table 3A.8.3 List of health states and disaggregated summary of cost impacts included in the economic evaluation
• Table 3A.8.4 List of health states and disaggregated summary of health outcomes included in the economic evaluation
• Table 3A.9.1 Examples of potential sources of translational uncertainty in the economic model and suggested scenario analyses
• Table 3A.9.2 Results of the sensitivity and scenario analyses characterising the uncertainty around the ICER
• Table 3B.1.1  Key assumptions and components of the cost-minimisation approach
• Table 4.1.1 Categories of data sources
• Table A1.1 Methods to collect and collate expert opinion
• Table A2.1 Search terms for the literature review
• Table A2.2 Record of search strategies
• Table A3.1 Trials (and associated reports) presented in the submission
• Table A3.2 Example comparison of event rates
• Table A3.3 Example summary list of trials included in the indirect comparison
• Table A4.1 Example factors that might cause comparative treatment effect heterogeneity
• Table A5.1 Biological reasoning for the effect of the medicine on the proposed surrogate measure
• Table A5.2 Characteristics of trials included in the assessment of the relationship between the proposed surrogate measure and the target clinical outcome
• Table A5.3 Results of randomised trials
• Table A5.4 Comparing randomised trial evidence and epidemiological evidence
• Table A5.5 Summary of conditions under which the relationship has been determined